{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:26:42Z","timestamp":1791919602042,"version":"4.3.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003385","name":"Georg-August-Universit\u00e4t G\u00f6ttingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003385","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00277-020-03974-y","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T05:13:14Z","timestamp":1584681194000},"page":"277-279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation"],"prefix":"10.1007","volume":"100","author":[{"given":"Annalen","family":"Bleckmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Dierks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Schildhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Hellige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,20]]},"reference":[{"issue":"9822","key":"3974_CR1","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","volume":"379","author":"EM Molyneux","year":"2012","unstructured":"Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S (2012) Burkitt\u2019s lymphoma. Lancet. 379(9822):1234\u20131244","journal-title":"Lancet."},{"issue":"6","key":"3974_CR2","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.hoc.2016.07.009","volume":"30","author":"K Dunleavy","year":"2016","unstructured":"Dunleavy K, Little RF, Wilson WH (2016) Update on Burkitt lymphoma. Hematol Oncol Clin North Am 30(6):1333\u20131343","journal-title":"Hematol Oncol Clin North Am"},{"issue":"8","key":"3974_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","volume":"119","author":"SA Meadows","year":"2012","unstructured":"Meadows SA, Vega F, Kashishian A et al (2012) PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 119(8):1897\u20131900","journal-title":"Blood."},{"issue":"2","key":"3974_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1517\/14656566.2016.1135130","volume":"17","author":"SA Graf","year":"2016","unstructured":"Graf SA, Gopal AK (2016) Idelalisib for the treatment of non-Hodgkin lymphoma. Expert Opin Pharmacother 17(2):265\u2013274","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"3974_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1586\/17474086.2015.1071663","volume":"8","author":"A Davies","year":"2015","unstructured":"Davies A (2015) Idelalisib for relapsed\/refractory indolent B-cell non-Hodgkin\u2019s lymphoma: an overview of pharmacokinetics and clinical trial outcomes. Expert Rev Hematol 8(5):581\u2013593","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"3974_CR6","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/ng.2468","volume":"44","author":"C Love","year":"2012","unstructured":"Love C, Sun Z, Jima D et al (2012) The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44(12):1321\u20131325","journal-title":"Nat Genet"},{"issue":"8","key":"3974_CR7","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.leu.2403847","volume":"19","author":"T Burmeister","year":"2005","unstructured":"Burmeister T, Schwartz S, Horst HA, Rieder H, G\u00f6kbuget N, Hoelzer D, Thiel E (2005) Molecular heterogeneity of sporadic adult Burkitt-type leukemia\/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features. Leukemia. 19(8):1391\u20131398","journal-title":"Leukemia."},{"key":"3974_CR8","doi-asserted-by":"crossref","unstructured":"Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM (2014) Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med 4(2)","DOI":"10.1101\/cshperspect.a014282"},{"key":"3974_CR9","doi-asserted-by":"publisher","first-page":"15044","DOI":"10.1038\/cddiscovery.2015.44","volume":"1","author":"G Wan","year":"2015","unstructured":"Wan G, Pehlke C, Pepermans R, Cannon JL, Lidke D, Rajput A (2015) The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cells. Cell Death Discov 1:15044","journal-title":"Cell Death Discov"},{"issue":"10","key":"3974_CR10","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1038\/oncsis.2016.65","volume":"5","author":"MR Sheen","year":"2016","unstructured":"Sheen MR, Marotti JD, Allegrezza MJ, Rutkowski M, Conejo-Garcia JR, Fiering S (2016) Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis. 5(10):e267","journal-title":"Oncogenesis."},{"issue":"12","key":"3974_CR11","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.18632\/oncotarget.716","volume":"3","author":"F Janku","year":"2012","unstructured":"Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R (2012) PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 3(12):1566\u20131575","journal-title":"Oncotarget."},{"issue":"2","key":"3974_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1006\/cimm.1998.1335","volume":"187","author":"AP Curnock","year":"1998","unstructured":"Curnock AP, Knox KA (1998) LY294002-mediated inhibition of phosphatidylinositol 3-kinase activity triggers growth inhibition and apoptosis in CD40-triggered Ramos-Burkitt lymphoma B cells. Cell Immunol 187(2):77\u201387","journal-title":"Cell Immunol"},{"key":"3974_CR13","first-page":"27","volume":"6","author":"LC Spender","year":"2014","unstructured":"Spender LC, Inman GJ (2014) Developments in Burkitt\u2019s lymphoma: novel cooperations in oncogenic MYC signaling. Cancer Manag Res 6:27\u201338","journal-title":"Cancer Manag Res"},{"issue":"1","key":"3974_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/0008-5472.CAN-12-1726","volume":"73","author":"F Janku","year":"2013","unstructured":"Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R (2013) PIK3CA mutation H1047R is associated with response to PI3K\/AKT\/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 73(1):276\u2013284","journal-title":"Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-03974-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-020-03974-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-03974-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:25:49Z","timestamp":1616199949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-020-03974-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["3974"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-03974-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,20]]},"assertion":[{"value":"13 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}